ATNM Quote, Financials, Valuation and Earnings

Aldeyra Therapeutics, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of --. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 380.77%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 90.29%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Aldeyra Therapeutics, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.29% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.984, suggesting its less volatile than the S&P 500 by 1.635%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 360.49x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Altimmune, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -380280%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Altimmune, Inc.'s return on equity of -56.24%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 380.77%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.67 which suggests that it could grow by 296.11%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Altimmune, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Altimmune, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.29% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.091, suggesting its less volatile than the S&P 500 by 90.87%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are larger than Altimmune, Inc. quarterly revenues of $5K. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 360.49x versus 17,811.29x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Assertio Holdings, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of 23.14%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Assertio Holdings, Inc.'s return on equity of -25.86%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 380.77%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $39.94 which suggests that it could grow by 236.46%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Assertio Holdings, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.29% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.775, suggesting its less volatile than the S&P 500 by 22.468%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than Assertio Holdings, Inc. quarterly revenues of $49.5M. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is lower than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 360.49x versus 4.42x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Avanos Medical, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -0.79%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Avanos Medical, Inc.'s return on equity of -52.63%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 380.77%. On the other hand Avanos Medical, Inc. has an analysts' consensus of $14.00 which suggests that it could fall by -7.96%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Avanos Medical, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Avanos Medical, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.303, which suggesting that the stock is 130.29% less volatile than S&P 500. In comparison Avanos Medical, Inc. has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.883%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avanos Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Avanos Medical, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than Avanos Medical, Inc. quarterly revenues of $177.8M. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is lower than Avanos Medical, Inc.'s net income of -$1.4M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Avanos Medical, Inc.'s PE ratio is 45.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 360.49x versus 1.01x for Avanos Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.